drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CAR-T)
drug_description
A gene-modified, autologous T-cell therapy expressing a chimeric antigen receptor targeting CD19. Upon binding CD19 on B-lineage cells, CAR-T cells activate independently of the native TCR, expand, release cytokines, and mediate perforin/granzyme-dependent cytotoxicity to clear CD19+ leukemic blasts, causing B-cell aplasia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous gene‑modified T cells expressing a CD19‑targeted chimeric antigen receptor bind CD19 on B‑lineage cells, triggering CAR signaling independent of the native TCR. This activates and expands the T cells, induces cytokine release, and mediates perforin/granzyme‑dependent cytotoxic killing of CD19+ leukemic blasts, resulting in depletion of malignant and normal B cells (B‑cell aplasia).
drug_name
Senl_B19 (S1904) autologous CD19 CAR-T cells
nct_id_drug_ref
NCT06581081